Nov 14,2023

Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award

Better Therapeutics announced it has been awarded Frost & Sullivan’s prestigious 2023 Best Practices Technology Innovation Leadership Award in the North American diabetes digital behavioral therapeutics industry. Frost & Sullivan's team of industry analysts conducted extensive research and in-depth interviews to evaluate multiple nominees before determining the final award recipient. "Receiving this award is a testament to the hard work and vision of our entire team. We are honored and motivated to continue our mission of advancing human health through the power of behavior change. It also reinforces the immense potential we see in making a meaningful impact on the lives of the 37 million individuals living with diabetes in the United States," said Frank Karbe, Chief Executive Officer at Better Therapeutics.

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023 TOP STORY

Beta Bionics Announces iLet Bionic Pancreas is Now Added to the Express Scripts National Commercial Formularies

Beta Bionics announced that effective November 10th, Express Scripts has added the iLet Bionic Pancreas and associated monthly supplies to their commercial national formulary offerings. For plans that cover the iLet Bionic Pancreas under their pharmacy benefit and use one of these formularies, this decision makes it faster and easier for eligible users to gain access to the iLet Bionic Pancreas. Historically, insulin pumps have been covered through the durable medical equipment (DME) insurance benefit where there may be significant up-front hardware costs to initiate therapy. In many instances the patient and payer share in the financial burden, which locks the patient to the insulin pump for the length of the pump’s four-to-five-year warranty. Coverage under a pharmacy benefit can reduce the potentially large up-front cost of the pump for both the patient and the payer, allowing patients to upgrade their insulin pump when new technology becomes available.

COLLABORATION PARTNERSHIP

#institution

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

Nemaura Medical, developer of a daily wear non-invasive glucose sensor and digital healthcare programs, announced the UK launch of its approach to metabolic health and weight management by integrating CGMs with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro. Their offering incl. education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets. The goal is to provide individuals with the tools they need to make lasting changes that support their overall well-being. The incorporation of GLP-1 agonists like Ozempic, Wegovy and Mounjaro adds a powerful layer of support for individuals seeking effective and sustainable weight loss.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023

Lilly to Participate in Evercore ISI HealthCONx Conference

Eli Lilly and Company will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023. Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:50 p.m., Eastern time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 15,2023 TOP STORY

Ypsomed doubles profits and confirms outlook

In the period under review, Ypsomed achieved a net profit of CHF 36.6 million (previous year CHF 15.4 million). The net profit margin doubled to 14.3% (previous year: 6.3%). In the Ypsomed Diabetes Care segment, sales of CHF 72.6 million (previous year: CHF 92.0 million) were recorded in the first half of 2023/24. Adjusted for the divestment of DiaExpert, a growth of 35.4% was achieved in continued business (previous year: adjusted CHF 53.6 million). Commercial sales of the mylife YpsoPump system increased by 153.6%, and the company shared that mylife Loop solution for the automated insulin delivery with a self-learning algorithm on the smartphone is approaching 40,000 users. On the other hand, their blood glucose monitoring systems business dropped by 7.3% due to the general decline in the market.

#insulin pump

#mobile app

#closed loop

View Analyst & Ambassador Comments
Go to original news
Nov 13,2023

Dario Publishes New Research Demonstrating That Dario Users That Increased Physical Activity Can Maintain Reduced Blood Glucose

DarioHealth announced new research presented at the Diabetes Technology Society 2023 Meeting on November 7, 2023. The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes. The new study examined the blood glucose and walking data of 989 Dario users to understand the impact of integrating clinical and behavioral data in a single digital app-based experience. The results demonstrated significantly reduced blood glucose levels in the first four months of using Dario and increased step levels in the same timeframe maintained for 12 months. In addition, the results demonstrated clinically significant reductions in blood glucose levels in users who tracked at least 400 steps per day. The research was conducted in partnership with the Integrative Pain Laboratory, School of Public Health at the University of Haifa.

CLINICAL STUDY

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023

Fitterfly showcases outcomes for children with type 2 Diabetes

In a groundbreaking move towards pediatric healthcare, Fitterfly announced its success with managing diabetes in children with Type 2 diabetes with personalised lifestyle interventions using its platform. While the key lies in achieving weight loss of around 10% with nutrition, fitness, stress and sleep management interventions, it is challenging to get children to stick to good habits. A total of 26 children enrolled into the Fitterfly Diabetes program in the last 2 years and of them 11 had type 2 diabetes while 15 had type 1 diabetes. Out of 11 children with type 2 diabetes, 7 finished the program and all of them have reduced HbA1c. The reduction was an average of 1.9 points which is equivalent or better than a combination diabetes oral therapy. In the same time frame, another 25 kids who enrolled in the Fitterfly weight loss program lost 4.1kg in 3 months signifying effectiveness of digitally led programs.

CLINICAL STUDY

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 09,2023 TOP STORY

Vida Health Announces $28.5 Million in Funding; Appoints Joe Murad CEO

Vida Health today announced it has closed $28.5 million in financing led by existing investors, including General Atlantic, Ally Bridge, Canvas Ventures, Hercules Capital, and other insiders. The company also named Joe Murad as Chief Executive Officer. Murad brings more than two decades of experience leading healthcare technology companies, with a demonstrated ability to guide venture-backed businesses from early stages through phases of significant growth. Murad succeeds Stephanie Tilenius, who will step down following nine years of service as Founder and CEO. Vida intends to use the investment to further scale and pursue ongoing growth opportunities, particularly in the rapidly expanding obesity and diabetes market.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Nov 09,2023

Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference

Senseonics announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY. Management is scheduled to present on Tuesday, November 14, 2023 from 4:45pm to 5:15pm ET.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 09,2023 TOP STORY

Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results

Senseonics reported financial results for the quarter ended September 30, 2023. Total revenue for the third quarter of 2023 was $6.1 million compared to $4.6 million for the third quarter of 2022. U.S. revenue was $3.9 million in the third quarter of 2023, and revenue outside the U.S. was $2.2 million in the third quarter of 2023. Net loss was $24.1 million, or $0.04 per share, in the third quarter of 2023 compared to a net loss of $60.4 million, or $0.13 per share, in the third quarter of 2022. Senseonics expects full year 2023 global net revenue to be at the midpoint of the $20 million to $24 million range.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES